Record Chinese Biotech Out Licensing Meets Rising US Scrutiny The record breaking value of licensing deals between Chinese biotechnology companies and international partners has set off alarm bells in Washington.
Policymakers are grappling with the implications of China's rising influence in the sector, which has surged to over $110 billion this year.
China's emergence as a global biotech powerhouse is undeniably a source of concern for US policymakers. They see it as a threat to American leadership in pharmaceuticals and medical technologies.